Señales en vivo de 1177.HK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 04:08):

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China...

Stats
Volumen de hoy	39.49M
Volumen promedio	52.37M
Capitalización de mercado	50.97B
EPS	HKD0 ( 2024-03-29 )
Próxima fecha de ganancias	( HKD0 ) 2024-06-14
Last Dividend	HKD0.0600 ( 2023-06-20 )
Next Dividend	HKD0 ( N/A )
P/E	25.18
ATR14	HKD0.00800 (0.29%)

Volumen Correlación

Largo: 0.02 (neutral)

Corto: 0.62 (weak)

Signal:(41.732) Neutral

Sino Biopharmaceutical Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sino Biopharmaceutical Correlación - Moneda/Commodity

-0.59
( weak negative )

-0.65
( weak negative )

0.00
( neutral )

-0.63
( weak negative )

Sino Biopharmaceutical Finanzas

Annual	2023
Ingresos:	HKD26.20B
Beneficio Bruto:	HKD21.21B (80.95 %)
EPS:	HKD0.0997

FY	2023
Ingresos:	HKD26.20B
Beneficio Bruto:	HKD21.21B (80.95 %)
EPS:	HKD0.0997

FY	2022
Ingresos:	HKD28.78B
Beneficio Bruto:	HKD22.98B (79.86 %)
EPS:	HKD0.270

FY	2021
Ingresos:	HKD26.86B
Beneficio Bruto:	HKD21.53B (80.15 %)
EPS:	HKD0.780

Financial Reports:

No articles found.

Sino Biopharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0600 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0600 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Sino Biopharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.59 - good (95.94%) | Divividend Growth Potential Score: 5.14 - Stable (2.85%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.00198	2004-09-16
Last Dividend	HKD0.0600	2023-06-20
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	70	--
Total Paid Out	HKD0.573	--
Avg. Dividend % Per Year	0.00%	--
Score	3.91	--
Div. Sustainability Score	9.59
Div.Growth Potential Score	5.14
Div. Directional Score	7.37	--

Next Divdend (Est)
(2024-08-29)

HKD0 Estimate 4.19 %

Dividend Stability

0.34 Poor

Dividend Score

3.91

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3759.HK	Ex Dividend Junior	2023-07-18	Annually	0.00%
1681.HK	Ex Dividend Knight	2023-06-08	Semi-Annually	0.00%
0716.HK	Ex Dividend Junior	2023-09-11	Annually	0.00%
2233.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%
1257.HK	No Dividend Player	2023-09-12	Annually	0.00%
0316.HK	Ex Dividend Knight	2023-08-31	Semi-Annually	0.00%
3996.HK	Ex Dividend Junior	2023-05-15	Annually	0.00%
1811.HK	Ex Dividend Junior	2023-06-06	Sporadic	0.00%
0839.HK	Ex Dividend Knight	2023-06-09	Semi-Annually	0.00%
0004.HK	Ex Dividend Knight	2023-08-29	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0711	1.500	8.58	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0247	1.200	9.18	10.00	[0 - 0.3]
returnOnEquityTTM	0.0519	1.500	-0.534	-0.801	[0.1 - 1]
payoutRatioTTM	0.404	-1.000	5.96	-5.96	[0 - 1]
currentRatioTTM	1.053	0.800	9.73	7.79	[1 - 3]
quickRatioTTM	0.755	0.800	-0.263	-0.210	[0.8 - 2.5]
cashRatioTTM	0.418	1.500	8.79	10.00	[0.2 - 2]
debtRatioTTM	0.197	-1.500	6.72	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.196	2.00	9.93	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.142	2.00	9.93	10.00	[0 - 20]
debtEquityRatioTTM	0.410	-1.500	8.36	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.788	1.000	0.197	0.197	[0.2 - 0.8]
operatingProfitMarginTTM	0.203	1.000	7.94	7.94	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.306	1.000	9.41	9.41	[0.2 - 2]
assetTurnoverTTM	0.347	0.800	-1.020	-0.816	[0.5 - 2]
Total Score				9.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	31.82	1.000	6.89	0	[1 - 100]
returnOnEquityTTM	0.0519	2.50	-0.343	-0.801	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.142	2.00	9.95	10.00	[0 - 30]
dividendYielPercentageTTM	3.12	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.196	2.00	9.93	10.00	[0 - 30]
payoutRatioTTM	0.404	1.500	5.96	-5.96	[0 - 1]
pegRatioTTM	0.329	1.500	-1.141	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.174	1.000	8.16	0	[0.1 - 0.5]
Total Score				5.14

Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.